MedTrace Logo

Characteristics of Ankylosing Spondylitis Associated Uveitis

NCT07113834 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 22

Last updated 2025-08-11

No results posted yet for this study

Summary

This study aims to understand the clinical characteristics associated with AAU in Egyptian AS patients, and the prognostic factors, in terms of the Corrected Distance Visual Acuity (CDVA).

Conditions

  • Uveitis

Interventions

DRUG

Adalimumab

A tumor necrosis factor-alpha (TNF-α) inhibitor used as a biologic agent for the treatment of ankylosing spondylitis. Administered subcutaneously as part of systemic immunomodulatory therapy.

DRUG

Systemic corticosteroids

Oral or intravenous corticosteroids (e.g., prednisolone) used to suppress systemic inflammation in cases of active AS or severe uveitis.

Sponsors & Collaborators

  • Benha University

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-01
Primary Completion
2023-09-01
Completion
2024-08-01

Countries

  • Egypt

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07113834 on ClinicalTrials.gov